Biotech Values

[BioSpecialist]

Alizyme PLC

Marketcap : 84 million GBP = 166,8 million US$
Cash: 16 million GBP = 31,3 million US$
Price: 39,75 p

Pipeline :
http://www.alizyme.com/alizyme/products/overview/

Presentation March 2008 << a must read
http://www.alizyme.com/alizyme/uploads/reports/Prelims2008FI…

Cetilistat (obesity + diabetes) start Phase III in 08

Renzapride (irritable bowel syndrome)1st Phase III results in April 08

Colal-Pred (ulcerative colitis) Phase III results in July and
MAA filing in 4Q 08

ATL-104 (mucositis) start Phase IIb in 08

28 March 08:
BROKERWATCH Alizyme upgraded to 'Buy' from 'Hold' at Investec

LONDON (Thomson Financial) - Investec Securities has upgraded Alizyme to 'Buy' from 'Hold',saying it believes the wait for a major partnering deal is 'almost over'.

The broker said it hopes that the company's obesity drug Cetilistat will deliver a licensing deal in the short term, and adds that the company's Irritable Bowel Syndrome drug Renzapride may also be outlicensed in the next 12 months.

It adds that further value may come from the imminent results from late stage trials on Renzapride, due to report in April, and the ulcerative colitis treatment COLAL-PRED, which it expects to be positive.

In a note to clients, the broker says it expects the company will not be coming back to the market for more cash for at least two years, pointing out that Alizyme has promised no more major R&D for at least two years without it being funded by a development partner.